Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (DE:82W)
FRANKFURT:82W
Hims & Hers Health (82W) Stock Price & Analysis
1 Followers
82W Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.36 - €15.60
Previous Close€11.43
Volume0.00
Average Volume (3M)1.60K
Market Cap
€2.50B
Enterprise Value€2.31B
Total Cash (Recent Filing)$212.50M
Total Debt (Recent Filing)$4.70M
Price to Earnings (P/E)N/A
Beta1.40
Next Earnings
May 06, 2024EPS Estimate
<€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding214,250,313
10 Day Avg. Volume464
30 Day Avg. Volume1,605
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)12.48
Price to Sales (P/S)4.47
Price to Cash Flow (P/CF)30.40
P/FCF Ratio15.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit5.65
Enterprise Value/Ebitda252.24
Forecast
1Y Price Target
€14.25Price Target Upside24.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Hims & Hers Health News
PremiumCompany Announcements
Hims & Hers Health Adds New Independent Director
PremiumCompany Announcements
Hims & Hers Health Welcomes New Independent DirectorBulls Say, Bears Say
Bulls Say
Business Strategy And GrowthEmerging categories like personalized weight loss and dermatology are projected to become significant revenue streams for HIMS.
Financial PerformanceThe company achieved its 2025 revenue/EBITDA targets ahead of schedule, indicating strong execution and financial performance.
Stock ValuationAnalyst increases the price target for the company's stock, suggesting a higher valuation based on growth outperformance.
Bears Say
Stock ValuationHIMS trades at a higher multiple than most peers, which could indicate that the stock is overvalued relative to its growth prospects.
User EngagementMarch witnessed the first month-over-month decline in Monthly Active Users since December 2021, highlighting decreased user engagement.
Website TrafficMarch also presented the first year-over-year decline in web visits, suggesting a potential downturn in the company's online presence.
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.41% Other Institutional Investors
99.59% Public Companies and
Individual Investors
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
82W FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was €5.36 and its highest was €15.60 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is May 06, 2024 which is in 6 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Feb 26, 2024. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.021 by €0.03.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is <€0.01.
How many shares outstanding does Hims & Hers Health have?
Currently, no data Available
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.021. Following the earnings report the stock price went up 33.439%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Royce & Associates LLC. It holds Hims & Hers Health’s shares valued at 2M.
---
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.25 (24.66% Upside)
€14.25 (24.66% Upside)
Blogger Sentiment
Bullish
DE:82W Sentiment 93%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.70%
12-Months-Change
Fundamentals
Return on Equity
-7.18%
Trailing 12-Months
Asset Growth
20.43%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
82W Company Deck
---
82W Earnings Call
Q4 2024
0:00 / 0:00
---
82W Revenue Breakdown
96.60% Online
3.40% Wholesale
---
82W Stock 12 Months Forecast
Average Price Target
€14.25
▲(24.66% Upside)
Technical Analysis
Hims & Hers Health
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Walgreens Boots Alliance
―
Teva Pharmaceutical
―
Best Analysts Covering 82W
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+54.77%
reiterated a buy rating 2 months ago
Copying Jack Wallace's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +54.77% per trade.
---